{"id":587741,"date":"2026-08-27T00:00:00","date_gmt":"2026-08-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0002-2026-biopharma-pulmonary-hypertension-landscape-forecast-disease-landscape-forecast-major-markets\/"},"modified":"2026-08-27T00:00:00","modified_gmt":"2026-08-27T00:00:00","slug":"dlsfcv0002-2026-biopharma-pulmonary-hypertension-landscape-forecast-disease-landscape-forecast-major-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0002-2026-biopharma-pulmonary-hypertension-landscape-forecast-disease-landscape-forecast-major-markets\/","title":{"rendered":"Pulmonary Hypertension &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (Major Markets)"},"content":{"rendered":"<p>Pulmonary hypertension (<abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr>) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> therapies is substantial, driven by premium pricing and polypharmacy. Current treatment dynamics are shaped by phosphodiesterase-5 inhibitors (<abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>-5) and endothelin receptor antagonists (<abbr data-abbreviation-entity=\"6318\" title=\"endothelin receptor antagonist\">ERA<\/abbr>s). Late-phase developments, including Gossamer Bio\u2019s seralutinib and United Therapeutics\u2019 ralinepag, signal continued innovation in expanding treatment options. Commercial interest in <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> remains strong, driven by the need for more effective, disease-modifying therapies and the absence of approved options for underserved patient populations. Our forecast model includes pulmonary arterial hypertension (<abbr data-abbreviation-entity=\"6187\" title=\"pulmonary arterial hypertension\">PAH<\/abbr>), <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> related to interstitial lung disease (<abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr>&#8211;<abbr data-abbreviation-entity=\"6866\" title=\"interstitial lung disease\">ILD<\/abbr>), and inoperable chronic thromboembolic pulmonary hypertension (<abbr data-abbreviation-entity=\"6317\" title=\"chronic thromboembolic pulmonary hypertension\">CTEPH<\/abbr>) patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How is the treatment landscape for <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> evolving across the major markets?<\/li>\n<li>What are <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s\u2019 views on Merck &#038; Co.\u2019s sotatercept and its unique nonvasodilatory mechanism of action, and how has its launch influenced their prescribing decision?<\/li>\n<li>How will late-phase emerging therapies, such as ralinepag and seralutinib, shape the <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> market and competitive positioning?<\/li>\n<li>How have generic launches impacted prescribing patterns and brand performance? How will these formulations affect the uptake of emerging therapies?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, EU5, Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading cardiologists and pulmonologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> by country, cause of the disease, and drug-treated rates.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"5930\" title=\"pulmonary hypertension\">PH<\/abbr> therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-587741","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-hypertension","biopharma-therapy-areas-pulmonary-hypertension","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/587741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=587741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}